Literature DB >> 31141015

Inhibitory Effect on the Hepatitis B Cells through the Regulation of miR-122-MAP3K2 signal pathway.

Songlin Chen1, Lei Yang1, Aiping Pan1, Siliang Duan2, Mingfen Li1, Ping Li1, Jingjing Huang1, Xingxin Gao3, Xiaoqi Huang1, Yinghui Lin1.   

Abstract

The aim of this study was to investigate the inhibitory effect of regulation of miR-122-MAP3K2 signal pathway on the hepatitis B cells. We detected the content of MAP3K2 from patients with HBV blood serum samples and analyzed the correlation between content of MAP3K2 and copies of HBV-DNA. Wound healing and Transwell assays were used to detect the function of cells from control group (wild type) and observer group (overexpresses miR-122). Secretion levels of HBsAg and MAP3K2 in the supernatant and level of MAP3K2 in cells were detected by ELISA and western blot, respectively. The results showed that there was a positive correlation between the copies of HBV-DNA and MAP3K2 in serum. In the assays involving detection of the number of HBV-DNA copies, the supernatant levels of HBsAg and MAP3K2, and the level of MAP3K2 in the cells, the rate of increase of these indicators significantly slowed as culture time. In conclusion, overexpression of miR-122 could inhibit the migration of hepatoblastoma cells; however, following transfection with miR-122, DNA synthesis and the secretion of HBsAg were inhibited. Overexpression of miR-122 can also downregulate MAP3K2. Consequently, we concluded that regulating the miR-122-MAP3K2 signaling pathway exerts an inhibitory effect in hepatitis B cells.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31141015     DOI: 10.1590/0001-3765201920180941

Source DB:  PubMed          Journal:  An Acad Bras Cienc        ISSN: 0001-3765            Impact factor:   1.753


  1 in total

1.  CircRNA circBACH1 facilitates hepatitis B virus replication and hepatoma development by regulating the miR-200a-3p/MAP3K2 axis.

Authors:  Na Du; Kailin Li; Yu Wang; Bo Song; Xuan Zhou; Shaoqiong Duan
Journal:  Histol Histopathol       Date:  2022-02-03       Impact factor: 2.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.